June 19th 2025
Median overall survival was 5 months longer in patients with small cell lung cancer (SCLC) who received tarlatamab instead of chemotherapy after progression following platinum-based chemotherapy.
Age Is Not a Risk Factor for Post-Mastectomy Reconstructive Surgery
Employers Express Their Concerns With Cancer Care at the COA Summit